Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation

References

• Wang Q, Arnst KE, Wang Y, Kumar G, Ma D, White SW, Miller DD, Li W, Li W. Structure-guided design, synthesis, and biological evaluation of (2-(1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) methanone (ABI-231) analogues targeting the colchicine binding site in tubulin. J Med Chem. 2019;62(14):6734–6750.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–265.
   PubMed Web of Science ®Google Scholar
• Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev. 2011;31(3):443–481.
   PubMed Web of Science ®Google Scholar
• Downing KH, Nogales E. Tubulin structure: insights into microtubule properties and functions. Curr Opin Struct Biol. 1998;8(6):785–791.
   PubMed Web of Science ®Google Scholar
• Hwang DJ, Wang J, Li W, Miller DD. Structural optimization of indole derivatives acting at colchicine binding site as potential anticancer agents. ACS Med Chem Lett. 2015;6(9):993–997.
   PubMed Web of Science ®Google Scholar
• Loong HH, Yeo W. Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. Onco Targets Ther. 2014;7:575–585.
   PubMed Web of Science ®Google Scholar
• Prota AE, Bargsten K, Diaz JF, Marsh M, Cuevas C, Liniger M, Neuhaus C, Andreu JM, Altmann KH, Steinmetz MO. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc Natl Acad Sci U S A. 2014;111(38):13817–13821.
   PubMed Web of Science ®Google Scholar
• Menchon G, Prota AE, Lucena-Agell D, Bucher P, Jansen R, Irschik H, Muller R, Paterson I, Diaz JF, Altmann KH, et al. A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. Nat Commun. 2018;9(1):2106.
   PubMedGoogle Scholar
• Muhlethaler T, Gioia D, Prota AE, Sharpe ME, Cavalli A, Steinmetz MO. Comprehensive analysis of binding sites in tubulin. Angew Chem Int Ed Engl. 2021;60(24):13331–13342.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang Y, Wang T, Jiang J, Botting CH, Liu H, Chen Q, Yang J, Naismith JH, Zhu X, et al. Pironetin reacts covalently with cysteine-316 of alpha-tubulin to destabilize microtubule. Nat Commun. 2016;7:12103.
   PubMed Web of Science ®Google Scholar
• Yang J, Yu Y, Li Y, Yan W, Ye H, Niu L, Tang M, Wang Z, Yang Z, Pei H, et al. Cevipabulin-tubulin complex reveals a novel agent binding site on alpha-tubulin with tubulin degradation effect. Sci Adv. 2021;7:eabg4168.
   PubMed Web of Science ®Google Scholar
• Matthew S, Chen QY, Ratnayake R, Fermaintt CS, Lucena-Agell D, Bonato F, Prota AE, Lim ST, Wang X, Diaz JF, et al. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site. Proc Natl Acad Sci U S A. 2021;118:e2021847118.
   PubMed Web of Science ®Google Scholar
• Steinmetz MO, Prota AE. Microtubule-targeting agents: strategies to hijack the cytoskeleton. Trends Cell Biol. 2018;28(10):776–792.
   PubMed Web of Science ®Google Scholar
• Bouchard H, Viskov C, Garcia-Echeverria C. Antibody–drug conjugates—a new wave of cancer drugs. Bioorg Med Chem Lett. 2014;24(23):5357–5363.
   PubMed Web of Science ®Google Scholar
• Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10(3):194–204.
   PubMed Web of Science ®Google Scholar
• Lu Y, Chen J, Xiao M, Li W, Miller DD. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res. 2012;29(11):2943–2971.
   PubMed Web of Science ®Google Scholar
• Gracheva IA, Shchegravina ES, Schmalz HG, Beletskaya IP, Fedorov AY. Colchicine alkaloids and synthetic analogues: current progress and perspectives. J Med Chem. 2020;63(19):10618–10651.
   PubMed Web of Science ®Google Scholar
• Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, Haber M. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 2001;61(15):5803–5809.
   PubMed Web of Science ®Google Scholar
• Prota AE, Danel F, Bachmann F, Bargsten K, Buey RM, Pohlmann J, Reinelt S, Lane H, Steinmetz MO. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. J Mol Biol. 2014;426(8):1848–1860.
   PubMed Web of Science ®Google Scholar
• Nerlekar N, Beale A, Harper RW. Colchicine–a short history of an ancient drug. Med J Aust. 2014;201(11):687–688.
   PubMed Web of Science ®Google Scholar
• Karamanou M, Tsoucalas G, Pantos K, Androutsos G. Isolating colchicine in 19th century: an old drug revisited. Curr Pharm Des. 2018;24(6):654–658.
   PubMed Web of Science ®Google Scholar
• Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol. 2010;48(5):407–414.
   PubMed Web of Science ®Google Scholar
• Mulkareddy V, Sokach C, Bucklew E, Bukari A, Sidlak A, Harrold IM, Pizon A, Reis S. Colchicine toxicity: the fatal masquerader. JACC Case Rep. 2020;2(4):678–680.
   PubMedGoogle Scholar
• Lu Y, Chen J, Wang J, Li CM, Ahn S, Barrett CM, Dalton JT, Li W, Miller DD. Design, synthesis, and biological evaluation of stable colchicine binding site tubulin inhibitors as potential anticancer agents. J Med Chem. 2014;57(17):7355–7366.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Arnst KE, Wang YX, Kumar G, Deng SS, Yang L, Li GB, Yang JB, White SW, Li W, et al. Heterocyclic-fused pyrimidines as novel tubulin polymerization inhibitors targeting the colchicine binding site: structural basis and antitumor efficacy. J Med Chem. 2018;61(4):1704–1718.
   PubMed Web of Science ®Google Scholar
• Fu D-J, Liu S-M, Li F-H, Yang J-J, Li J. Antiproliferative benzothiazoles incorporating a trimethoxyphenyl scaffold as novel colchicine site tubulin polymerisation inhibitors. J Enzyme Inhib Med Chem. 2020;35(1):1050–1059.
   PubMed Web of Science ®Google Scholar
• Wang G, Liu W, Fan M, He M, Li Y, Peng Z. Design, synthesis and biological evaluation of novel thiazole-naphthalene derivatives as potential anticancer agents and tubulin polymerisation inhibitors. J Enzyme Inhib Med Chem. 2021;36(1):1694–1702.
   PubMed Web of Science ®Google Scholar
• Chen L, Ji T-Y, Huo X-S, Zeng Z-Y, Ye W-X, Dai C-C, Zhang Y-Q, You W-W, Zhao P-L. Rational design, synthesis and biological evaluation of novel 2-(substituted amino)-[1,2,4]triazolo[1,5-a]pyrimidines as novel tubulin polymerization inhibitors. Eur J Med Chem. 2022;244:114864.
   PubMed Web of Science ®Google Scholar
• Huo XS, Jian XE, Ou-Yang J, Chen L, Yang F, Lv DX, You WW, Rao JJ, Zhao PL. Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines. Eur J Med Chem. 2021;220:113449.
   PubMed Web of Science ®Google Scholar
• Ma W, Chen P, Huo X, Ma Y, Li Y, Diao P, Yang F, Zheng S, Hu M, You W, et al. Development of triazolothiadiazine derivatives as highly potent tubulin polymerization inhibitors: Structure-activity relationship, in vitro and in vivo study. Eur J Med Chem. 2020;208:112847.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT04844749.
   Google Scholar
• ClinicalTrials.gov Identifier: NCT05079360.
   Google Scholar
• Markowski MC, Tutrone R, Pieczonka C, Barnette KG, Getzenberg RH, Rodriguez D, Steiner MS, Saltzstein DR, Eisenberger MA, Antonarakis ES. A phase Ib/II study of sabizabulin, a novel oral cytoskeleton disruptor, in men with metastatic castration-resistant prostate cancer with progression on an androgen receptor-targeting agent. Clin Cancer Res. 2022;28(13):2789–2795.
   PubMed Web of Science ®Google Scholar
• Liu W, Jia H, Guan M, Cui M, Lan Z, He Y, Guo Z, Jiang R, Dong G, Wang S. Discovery of novel tubulin inhibitors targeting the colchicine binding site via virtual screening, structural optimization and antitumor evaluation. Bioorg Chem. 2022;118:105486.
   PubMed Web of Science ®Google Scholar
• Wang S, Fang K, Dong G, Chen S, Liu N, Miao Z, Yao J, Li J, Zhang W, Sheng C. Scaffold diversity inspired by the natural product evodiamine: discovery of highly potent and multitargeting antitumor agents. J Med Chem. 2015;58(16):6678–6696.
   PubMed Web of Science ®Google Scholar
• Kramer N, Walzl A, Unger C, Rosner M, Krupitza G, Hengstschläger M, Dolznig H. In vitro cell migration and invasion assays. Mutat Res. 2013;752(1):10–24.
   PubMed Web of Science ®Google Scholar
• Romagnoli R, Baraldi PG, Salvador MK, Prencipe F, Lopez-Cara C, Schiaffino Ortega S, Brancale A, Hamel E, Castagliuolo I, Mitola S, et al. Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin. J Med Chem. 2015;58(7):3209–3222.
   PubMed Web of Science ®Google Scholar
• Al-Bahlani S, Al-Dhahli B, Al-Adawi K, Al-Nabhani A, Al-Kindi M. Platinum-based drugs differentially affect the ultrastructure of breast cancer cell types. Biomed Res Int. 2017;2017:3178794.
   PubMed Web of Science ®Google Scholar
• Zhang S, Mercado-Uribe I, Liu J. Tumor stroma and differentiated cancer cells can be originated directly from polyploid giant cancer cells induced by paclitaxel. Int J Cancer. 2014;134(3):508–518.
   PubMed Web of Science ®Google Scholar
• Zdioruk M, Want A, Mietelska-Porowska A, Laskowska-Kaszub K, Wojsiat J, Klejman A, Użarowska E, Koza P, Olejniczak S, Pikul S, et al. A new inhibitor of tubulin polymerization kills multiple cancer cell types and reveals p21-mediated mechanism determining cell death after mitotic catastrophe. Cancers. 2020;12(8):2161.
   PubMed Web of Science ®Google Scholar
• Nakagawa-Goto K, Oda A, Hamel E, Ohkoshi E, Lee K-H, Goto M. Development of a novel class of tubulin inhibitor from desmosdumotin B with a hydroxylated bicyclic B-ring. J Med Chem. 2015;58(5):2378–2389.
   PubMed Web of Science ®Google Scholar
• Chen H, Deng S, Albadari N, Yun M-K, Zhang S, Li Y, Ma D, Parke DN, Yang L, Seagroves TN, et al. Design, synthesis, and biological evaluation of stable colchicine-binding site tubulin inhibitors 6-aryl-2-benzoyl-pyridines as potential anticancer agents. J Med Chem. 2021;64(16):12049–12074.
   PubMed Web of Science ®Google Scholar
• Gupta S, Kass GE, Szegezdi E, Joseph B. The mitochondrial death pathway: a promising therapeutic target in diseases. J Cell Mol Med. 2009;13(6):1004–1033.
   PubMed Web of Science ®Google Scholar